New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 19, 2013
19:03 EDTSYNSynthetic Biologics reiterates collaboration with Intrexon still in effect
Synthetic Biologics reiterated that the exclusive channel collaboration agreement dated August 6, 2012 between the company and Intrexon remains in effect. This agreement governs a "channel collaboration" arrangement for the use of Intrexon's technology relating to the identification, design and production of human antibodies and DNA vectors for the development and commercialization of a series of monoclonal antibody therapies for the treatment of certain serious infectious diseases.
News For SYN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 22, 2014
06:59 EDTSYNSynthetic Biologics granted patent for C. difficile
Synthetic Biologics has been issued a Notice of Allowance by the USPTO for a composition of matter patent application that covers the lead product in its C. difficile program, SYN-004. This is Synthetic Biologics' first allowed patent application directly pertaining to SYN-004 in the U.S. SYN-004 is Synthetic Biologics' novel oral enzyme drug candidate designed as the first and only prophylactic treatment intended to prevent the development of C. difficile infections.
October 20, 2014
17:18 EDTSYNGreat Point Partners reports 9.98% passive stake in Synthetic Biologics
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use